Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients.

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? Clin Med Insights Oncol (2016) 0.75

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood (2006) 7.30

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia (2003) 7.04

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med (2003) 6.68

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol (2011) 4.32

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia (2003) 4.31

Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia (2012) 2.80

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood (2008) 2.80

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood (2009) 2.29

Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol (2008) 0.87

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res (2013) 0.85

Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples. J Mol Diagn (2013) 0.82

Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk (2012) 0.80

Comparison of ABO antibody titers on the basis of the antibody detection method used. Ann Lab Med (2014) 0.92

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica (2016) 0.90

A case of donor-derived granulocytic sarcoma after allogeneic hematopoietic stem cell transplantation. Korean J Hematol (2010) 0.85

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget (2016) 0.82

Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematol (2010) 0.80

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. Blood Res (2015) 0.79

Autoimmune hemolytic anemia predominantly associated with IgA anti-E and anti-c. J Korean Med Sci (2002) 0.77

Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea. Blood Res (2013) 0.75

Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication. Ann Lab Med (2016) 0.75

A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient. Ann Lab Med (2015) 0.75

Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. J Korean Med Sci (2015) 0.75

A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma. Ann Lab Med (2017) 0.75

Identification of cell morphology parameters from automatic hematology analyzers to predict the peripheral blood CD34-positive cell count after mobilization. PLoS One (2017) 0.75

Current trends in domestic status and insurance policy for use of plasma. Korean J Hematol (2010) 0.75

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget (2017) 0.75

A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization. PLoS One (2017) 0.75

Plasma cell leukemia with rouleaux formation involving neoplastic cells and RBC. Korean J Hematol (2011) 0.75